WESTLAKE VILLAGE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) — MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKind’s BluHale technology system.